Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy
Titel:
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy
Auteur:
Friedlander, M. Rau, J. Lee, C.K. Meier, W. Lesoin, A. Kim, J.-W. Poveda, A. Buck, M. Scambia, G. Shimada, M. Hilpert, F. King, M.T. Debruyne, P. Bologna, A. Malander, S. Monk, B.J. Petru, E. Calvert, P. Herzog, T.J. Barrett, C. du Bois, A.